Ionis Pharmaceuticals INC Form 4 insider transactions

Ionis Pharmaceuticals EVP of Research, Eric Swayze, reports the vesting and sale of common stock, along with the grant of new performance and restricted stock units.

EVP, Chief Clinical Development Officer of Ionis Pharmaceuticals, Eugene Schneider, exercised stock options and sold shares to cover tax obligations.

Patrick R. O'Neil, EVP CLO & General Counsel at Ionis Pharmaceuticals, executed stock options and sold shares to cover tax obligations.

Ionis Pharmaceuticals CEO Brett Monia acquired shares through vesting of restricted stock units and sold shares to cover tax obligations.

An Ionis Pharmaceuticals executive, Kyle Jenne, received grants of performance and restricted stock units.

Executive Vice President and CFO of Ionis Pharmaceuticals, Elizabeth Hougen, reports the acquisition and disposal of company stock and derivative securities.

Richard S. Geary, EVP and Chief Development Officer at Ionis Pharmaceuticals, reported the acquisition of stock units and the sale of shares to cover tax obligations.

Executive Vice President Shannon L. Devers of Ionis Pharmaceuticals reported the acquisition of shares through vesting and the sale of shares to cover tax obligations.

Executive Vice President of Corporate and Development Operations at Ionis Pharmaceuticals, Brian Birchler, reports the vesting of restricted stock units, subsequent sale of shares, and grant of new performance and restricted stock units.

An Ionis Pharmaceuticals executive, C. Frank Bennett, exercised stock options and sold shares to cover tax obligations, while also receiving new restricted stock units.

Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals, Joseph Baroldi, reports acquisition and disposal of company stock and derivative securities.

EVP and Chief Development Officer of Ionis Pharmaceuticals, Richard S. Geary, reports the acquisition of 22,000 stock options.

EVP Eric Swayze receives stock options, and a grant is made to his son, under Ionis Pharmaceuticals' equity incentive plan.

Eugene Schneider, EVP, Chf Clinical Develop Ofcr of Ionis Pharmaceuticals, reports the acquisition of stock options.

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, received 22,000 non-qualified stock options on January 2, 2025.

Ionis Pharmaceuticals CEO Brett P. Monia was granted stock options to purchase 86,263 shares of common stock at an exercise price of $34.69 on January 2, 2025.

EVP, Chief Global Product Strategy Officer of Ionis Pharmaceuticals, Kyle Jenne, was granted stock options for 18,700 shares on January 2, 2025.

Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, reports the grant of stock options for 31,000 shares on January 2, 2025.

Shannon L. Devers, EVP and Chief Human Resources Officer at Ionis Pharmaceuticals, was granted 22,000 stock options on January 2, 2025.

Brian Birchler, EVP at Ionis Pharmaceuticals, received 22,000 stock options on January 2, 2025, according to a recent SEC filing.

C. Frank Bennett, EVP and Chief Scientific Officer at Ionis Pharmaceuticals, was granted 22,000 stock options on January 2, 2025.

Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals, was granted stock options, with a portion also granted to his spouse.

Director Michael R. Hayden of Ionis Pharmaceuticals acquired 5,000 shares of common stock through two transactions on December 23, 2024.

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, sold 1,194 shares of common stock at a weighted average price of $37.921 per share under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals CEO Brett P. Monia sold 6,630 shares of common stock at a weighted average price of $38.0534, as part of a pre-arranged 10b5-1 trading plan.

Joseph Loscalzo, a director at Ionis Pharmaceuticals, sold 13,508 shares of common stock at a weighted average price of $37.861, as part of a pre-arranged 10b5-1 trading plan.

EVP of Research at Ionis Pharmaceuticals, Eric Swayze, reports acquisition and disposal of common stock and restricted stock units.

Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals, was granted 11,280 Restricted Stock Units (RSUs) on October 15, 2024, according to a Form 4 filing.

Shannon L. Devers, EVP and Chief Human Resources Officer of Ionis Pharmaceuticals, reports the grant of stock options.

Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reports the purchase of common stock and the disposal of common stock held indirectly.